Multiple injections of pegylated liposomal doxorubicin: Pharmacokinetics and therapeutic activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 1058-1067

  Charrois, Gregory J R ^a   Allen, Theresa M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HAND FOOT SYNDROME; INJECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; TREATMENT OUTCOME; TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; DOXORUBICIN; FEMALE; LIPOSOMES; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 0041430798     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.053413     Document Type: Article

References (39)

1. Adlakha-Hutcheon G, Bally MB, Shew CR, and Madden TD (1999) Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17:775-779.
2. Allen TM and Hansen CB (1991) Pharmacokinetics of STEALTH versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133-141.
3. Allen TM, Hansen CB, and Guo LSS (1993) Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta 1150:9-16.
4. Allen TM, Hansen CB, and Lopes de Menezes DE (1995) Pharmacokinetics of long circulating liposomes. Adv Drug Delivery Rev 16:267-284.
5. Allen TM, Hansen CB, Martin F, Redemann C, and Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36.
6. Amantea M, Newman MS, Sullivan TM, Forrest A, and Working PK (1999) Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 18:17-26.
7. Aslakson CJ and Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399-1405.
8. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, and Mayer LD (1989) Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023:133-139.
9. Berry G, Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, and Martin FJ (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711-716.
10. Charrois GJR and Allen TM (2003) Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 1609:102-108.
11. Cowens JW, Creaven PJ, Greco WR, Brenner DE, Tung Y, Osto M, Pilkiewicz F, Ginsberg R, and Petrelli N (1993) Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 53:2796-2802.
12. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IA, and Scherphof GL (1995) Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer 61:716-721.
13. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, and Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50:219-244.
14. Gabizon A (2001) Stealth liposomal doxorubicin: an analysis of the effect of dose on tumor targeting and therapy, Fifth International Conference: Liposome Advances: Progress in Drug and Vaccine Delivery (Gregoriadis G and Florence AT eds) 17-21 December 2001, University of London, School of Pharmacy, London, England.
15. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, and Barenholz Y (1994a) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res 54:987-992.
16. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, Ben-Dor CG, Rabello E, Cass Y, Peretz T, et al. (1994b) Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 33:779-786.
17. Goldberg SN, Kamel IR, Kruskal JB, Reynolds K, Monsky WL, Stuart KE, Ahmed M, and Raptopoulos V (2002) Radiofrequency ablation of hepatic tumor: increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgenol 179:93-101.
18. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, and Sharpington T (2000) Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18:3093-3100.
19. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, and VonRoenn J (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75:2169-2173.
20. Hamilton A, Biganzoli L, Coleman R, Mauriac L, Hennebert P, Awada A, Nooij M, Beex L, Piccart M, Van Hoorebeeck I, et al. (2002) EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol 13:910-918.
21. Hensley ML, Hoppe B, Leon L, Sabbatini P, Aghajanian C, Chi D, and Spriggs DR (2001) The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecol Oncol 82:464-469.
22. Hong R-L, Huang C-J, Tseng Y-L, Pang VF, Chen S-T, Liu J-J, and Chang F-H (1999) Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin Cancer Res 5:3645-3652.
23. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, and Dewhirst MW (2000) Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60:6950-6957.
24. Krishna R, Ghiu G, and Mayer LD (2001) Visualization of bioavailable liposomal doxorubicin using a non-perturbing confocal imaging technique. Histol Histopathol 16:693-699.
25. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, and Gabizon A (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136:1474-1480.
26. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, and Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037-1047.
27. Maeda H, Wu J, Sawa T, Matsumura Y, and Hori K (2000) Tumor vascular permeability and the ERP effect in macromolecular therapeutics: a review. J Control Release 65:271-284.
28. Matsumura Y and Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 6:6387-6392.
29. Mayer LD, Dougherty G, Harasym TO, and Bally MB (1997) The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280:1406-1414.
30. Moase E, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, Ding L, Krantz M, and Allen TM (2001) Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta 1510:43-55.
31. Muggia F, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, et al. (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993.
32. Needham D, Anyarambhatla G, Kong G, and Dewhirst MW (2000) A new tempertature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumour xenograft model. Cancer Res 60:1197-1201.
33. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, and Mamelok RD (1997) Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 15:653-659.
34. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, and Martin FJ (1991) Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88:11460-11464.
35. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, and Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15:3185-3191.
36. 2. Ann Oncol 11:1029-1033.
37. Storm G, ten Kate MT, Working PK, and Bakker-Woudenberg IAJM (1998) Doxorubicin entrapped in sterically stabilzed liposomes: effects on bacterial blood clearance of the mononucear phagocyte system. Clin Cancer Res 3:111-115.
38. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, and Gabizon A (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777-1785.
39. Working P and Dayan AD (1996) Pharmacological-toxocological expert report: Caelyx (Stealth liposomal doxorubicin HCl). Hum Exp Toxicol 15:751-785.